KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Accumulated Expenses (2016 - 2025)

Travere Therapeutics' Accumulated Expenses history spans 15 years, with the latest figure at $126.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 46.5% year-over-year to $126.0 million; the TTM value through Dec 2025 reached $126.0 million, up 46.5%, while the annual FY2025 figure was $126.0 million, 46.5% up from the prior year.
  • Accumulated Expenses reached $126.0 million in Q4 2025 per TVTX's latest filing, up from $105.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $139.6 million in Q1 2024 to a low of $46.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $87.6 million, with a median of $84.8 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: surged 62.75% in 2024, then plummeted 44.76% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $75.2 million in 2021, then increased by 27.35% to $95.7 million in 2022, then increased by 24.28% to $119.0 million in 2023, then decreased by 27.7% to $86.0 million in 2024, then soared by 46.5% to $126.0 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Accumulated Expenses are $126.0 million (Q4 2025), $105.8 million (Q3 2025), and $81.7 million (Q2 2025).